VerastemVSTM
About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Employees: 78
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
322% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 9
151% more call options, than puts
Call options by funds: $414K | Put options by funds: $165K
120% more capital invested
Capital invested by funds: $79.5M [Q3] → $175M (+$95.6M) [Q4]
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
18% more funds holding
Funds holding: 76 [Q3] → 90 (+14) [Q4]
10.0% more ownership
Funds ownership: 66.08% [Q3] → 76.08% (+10.0%) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Jefferies Kelly Shi 36% 1-year accuracy 4 / 11 met price target | 115%upside $15 | Buy Initiated | 10 Apr 2025 |
Mizuho Mara Goldstein 100% 1-year accuracy 2 / 2 met price target | 15%upside $8 | Outperform Maintained | 9 Apr 2025 |
Guggenheim Michael Schmidt 41% 1-year accuracy 15 / 37 met price target | 101%upside $14 | Buy Maintained | 24 Mar 2025 |
HC Wainwright & Co. Sean Lee 60% 1-year accuracy 18 / 30 met price target | 43%upside $10 | Buy Maintained | 24 Mar 2025 |
RBC Capital Gregory Renza 27% 1-year accuracy 20 / 75 met price target | 101%upside $14 | Outperform Maintained | 21 Mar 2025 |
Financial journalist opinion
Based on 5 articles about VSTM published over the past 30 days









